Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZOMIG | Amneal Pharmaceuticals | N-021450 RX | 2003-09-30 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
zolmiptriptan | ANDA | 2024-07-04 |
zolmitriptan | ANDA | 2025-05-02 |
zolmitriptan od | ANDA | 2024-12-18 |
zomig | ANDA | 2024-02-14 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
migraine disorders | EFO_0003821 | D008881 | G43 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | 2 | 2 | — | 5 |
Headache | D006261 | — | R51 | — | — | — | 1 | — | 1 |
Drug common name | Zolmitriptan |
INN | zolmitriptan |
Description | Zolmitriptan is a member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is a member of tryptamines and an oxazolidinone. It is functionally related to a N,N-dimethyltryptamine. |
Classification | Small molecule |
Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12 |
PDB | — |
CAS-ID | 139264-17-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1185 |
ChEBI ID | 10124 |
PubChem CID | 60857 |
DrugBank | DB00315 |
UNII ID | 2FS66TH3YW (ChemIDplus, GSRS) |